Dr. Gerard Vockley, MD, PhD
Claim this profileUPMC Children's Hospital of Pittsburgh
Studies Phenylketonuria
Studies Inborn Errors of Lipid Metabolism
13 reported clinical trials
16 drugs studied
Affiliated Hospitals
Clinical Trials Gerard Vockley, MD, PhD is currently running
ELAPRASE + Prophylactic Therapy
for Hunter Syndrome
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome. In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR. Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic ITR will consist of a 5-week cycle of: Rituximab (intravenously \[IV\], weekly for 4 weeks); Methotrexate (oral, 3 times per week for 5 weeks) and intravenous immunoglobulin (IVIG) (IV, every 4 weeks of the cycle). Following the completion of 1 cycle, an assessment will be made at Month 6, 12, and 18 regarding the need for administering another 5-week cycle of the ITR. Participants will be in the study for approximately 112 weeks (including 6 weeks for screening, up to 104 weeks for treatment, and 2 weeks for follow-up).
Recruiting3 awards Phase 48 criteria
PTC923
for Phenylketonuria
This trial is testing the safety of a medication called PTC923 in people with phenylketonuria (PKU). PKU patients need to manage their blood phenylalanine levels carefully. PTC923 aims to help control these levels, making it easier for patients to manage their condition. PTC923 is a newer treatment for PKU, following earlier treatments like sapropterin and pegvaliase.
Recruiting2 awards Phase 34 criteria
More about Gerard Vockley, MD, PhD
Clinical Trial Related1 year of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Gerard Vockley, MD, PhD has experience with
- Placebo
- None
- HMI-103
- SYNB1934
- KB195
- REN001
Breakdown of trials Gerard Vockley, MD, PhD has run
Phenylketonuria
Inborn Errors of Lipid Metabolism
Medium-Chain Acyl-CoA Dehydrogenase Deficiency
Syndrome
Pyridoxine-Dependent Epilepsy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gerard Vockley, MD, PhD specialize in?
Gerard Vockley, MD, PhD focuses on Phenylketonuria and Inborn Errors of Lipid Metabolism. In particular, much of their work with Phenylketonuria has involved treating patients, or patients who are undergoing treatment.
Is Gerard Vockley, MD, PhD currently recruiting for clinical trials?
Yes, Gerard Vockley, MD, PhD is currently recruiting for 4 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Gerard Vockley, MD, PhD has studied deeply?
Yes, Gerard Vockley, MD, PhD has studied treatments such as Placebo, None, HMI-103.
What is the best way to schedule an appointment with Gerard Vockley, MD, PhD?
Apply for one of the trials that Gerard Vockley, MD, PhD is conducting.
What is the office address of Gerard Vockley, MD, PhD?
The office of Gerard Vockley, MD, PhD is located at: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15224 United States. This is the address for their practice at the UPMC Children's Hospital of Pittsburgh.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.